13A-1091211
US、TW pending
We have constructed two recombinant vaccinia virus strains expressing SARS-CoV-2 Spike protein, named MVA-S and v-NY-S. We also developed two major combinations of prime-boost immunization regimens to achieve the best protection in golden hamsters after challenging with SARS-CoV-2. The first prime-boost regimen uses 5x107PFU of MVA-S via intramuscular injection into hamsters, wait for 4 weeks and then boosts intramuscularly again with 107PFU of MVA-S virus. The second prime-boost regimen uses skin scarification to introduce 107PFU (or 5x107PFU) of v-NY-S, wait for 4 weeks and then boost intramuscularly with 107PFU of MVA-S virus.
- Affordable price, easy production and convenient transport without cold chain.
- Strong immune activation with various prime-boost combination.
- Long term protection
Develop as a SARS-CoV-2 vaccine
Wen Chang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Development of recombinant vaccinia viruses as vaccines against SARS-CoV-2